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Abstract
Background: After more than 25 years, public health programs have not been able to sufficiently
reduce the number of new HIV infections. Over 7,000 people become infected with HIV every day.
Lack of convincing evidence of cost-effectiveness (CE) may be one of the reasons why
implementation of effective programs is not occurring at sufficient scale. This paper identifies,
summarizes and critiques the CE literature related to HIV-prevention interventions in low- and
middle-income countries during 2005-2008.
Methods:  Systematic identification of publications was conducted through several methods:
electronic databases, internet search of international organizations and major funding/implementing
agencies, and journal browsing. Inclusion criteria included: HIV prevention intervention, year for
publication (2005-2008), setting (low- and middle-income countries), and CE estimation (empirical
or modeling) using outcomes in terms of cost per HIV infection averted and/or cost per disability-
adjusted life year (DALY) or quality-adjusted life year (QALY).
Results: We found 21 distinct studies analyzing the CE of HIV-prevention interventions published
in the past four years (2005-2008). Seventeen CE studies analyzed biomedical interventions; only a
few dealt with behavioral and environmental/structural interventions. Sixteen studies focused on
sub-Saharan Africa, and only a handful on Asia, Latin America and Eastern Europe. Many HIV-
prevention interventions are very cost effective in absolute terms (using costs per DALY averted),
and also in country-specific relative terms (in cost per DALY measured as percentage of GDP per
capita).
Conclusion: There are several types of interventions for which CE studies are still not available
or insufficient, including surveillance, abstinence, school-based education, universal precautions,
prevention for positives and most structural interventions. The sparse CE evidence available is not
easily comparable; thus, not very useful for decision making. More than 25 years into the AIDS
epidemic and billions of dollars of spending later, there is still much work to be done both on costs
and effectiveness to adequately inform HIV prevention planning.
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Background
After more than 25 years into an epidemic of a completely
preventable disease, public health programs have not
been able to sufficiently reduce the number of new HIV
infections around the world. The global AIDS epidemic
update reports that 2.7 million people acquired HIV dur-
ing 2007 [1]; over 7,000 people were infected with HIV
every day [2]. Prevention may save millions of people, but
it is far from working well. One of the reasons why imple-
mentation of effective programs is not occurring at suffi-
cient scale is because of insufficient evidence of the cost-
effectiveness (CE) of prevention interventions and pro-
grams [3].
Cost-effectiveness analysis (CEA) is a comparison of two
or more alternatives in terms of their costs and effective-
ness through a CE ratio: the difference in costs over the
difference in effectiveness. Mathematical and epidemio-
logical models are often required to simulate final out-
comes from available data on intermediate outcomes. To
make comparisons across different types of interventions
and countries, CEA often uses a summary measure of
effectiveness such as the quality- or disability-adjusted life
years (QALYs/DALYs) gained/averted through interven-
tions [4,5]. CEA can help decision-makers allocate
resources and define priorities among a range of interven-
tions.
Many studies on the CE of HIV-prevention interventions
have appeared in the past four years (2005-2008), making
substantial contributions to the literature since the publi-
cation of the Disease Control Priorities Project (DCPP) [3]
and other reviews [6,7]. New interventions have emerged,
increasing the debate for assessing resource allocation [8].
Furthermore, there are imperative reasons to conduct a
new CE review. First, a dearth of CE data is available for
HIV prevention [9,10]. Second, there is a need to make the
limited, existing CE data available to program managers
and implementers. Third, we need to update regularly the
existing data to facilitate access: it may be difficult for deci-
sion-makers by themselves to easily absorb all the mate-
rial that has appeared in recent years.
The objective of this paper is twofold: first it systematically
reviews and summarizes the recent literature in terms of
CE; second, it critiques and analyzes the comparability of
the recent CE studies.
Methods
The electronic databases utilized for the literature search
were: Web of Science, Social Science Citation Index,
PubMed (National Library of Medicine) and the American
Economic Association's electronic bibliography of eco-
nomic literature (EconLit). On-going projects by
UNAIDS, World Health Organization (WHO), PEPFAR,
and Global Fund to Fight AIDS, Tuberculosis and Malaria
were also probed.
In addition, we reviewed the following scientific journals
to find any articles not identified through keywords via
electronic means: AIDS, BMJ, Bulletin of the World Health
Organization, Cost-effectiveness and Resource Allocation,
Health Policy and Planning, International Journal of STDs and
AIDS, JAMA, Journal of Acquired Immune Deficiency Syn-
drome, PLoS Medicine, Sexually Transmitted Diseases, and
The Lancet. Finally, suggestions from experts in the field
complemented our search strategy.
Table 1: Search Terms and Restrictions
Domain Description Search terms
Economic/evaluation Economic and Impact evaluation Cost, costing, effectiveness, cost-effectiveness, prevention, impact, HIV, AIDS
Setting Low- and middle-income countries (as per World Bank definition [11]); developing 
countries, third-world countries,, limited-resource settings 
(exclusion: high-income country)
Intervention Prevention interventions HIV/AIDS; school-based education; abstinence education; voluntary counseling and 
testing (VCT); peer-based programs; condom promotion and distribution; 
information, education and communication (IEC); condom social marketing (CSM); 
sexually transmitted infection (STI) treatment ("positive prevention"); antiretroviral 
treatment/therapy (ART); mother-to-child HIV transmission (MTCT) interventions; 
feeding substitution; harm reduction; needle exchange; drug substitution; blood safety; 
universal precautions; post-exposure prophylaxis; women empowerment; behavior-
change programs; efficacy and effectiveness; structural interventions; social 
interventions; self-help and support groups; male circumcision (MC).
Publication Dates January 2005 to
December 2008BMC Public Health 2009, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2458/9/S1/S5
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Using the search terms and restrictions listed in Table 1 we
retrieved 506 references. A preliminary analysis of
abstracts was conducted, and led to the retrieval of 90
works for full-text assessment.
We systematically reviewed the literature for CEA studies
that compared a new intervention or program modifica-
tion with a comparison case (no-intervention, status quo,
or other intervention). The studies were classified by type
of intervention (behavioral, biomedical or structural) as
well as the specific prevention intervention. Based on
these criteria, we reviewed 21 distinct CE studies.
The information about costs and effectiveness was
abstracted into a checklist for each of the studies fulfilling
the search criteria. We noted the place of the intervention,
the target population, and the main issue addressed, as
well as the type of epidemic in which the program took
place (concentrated, generalized) and the main CE results.
We reported CE studies that used cost per HIV infection
averted (HIA) or cost per DALY/QALY averted/gained as
the main outcome variable.
The classification of interventions in this review comes
from a typology used by the UNAIDS and the World
Health Organization (WHO) [9] and recent reviews on
HIV prevention published in the Lancet [10,12-14]. Nev-
ertheless, some of the interventions fall under two or
more of the types presented. A better typology should rec-
ognize the independence of intervention and target popu-
lation. The lack of clarity in intervention typology is most
acute in the area of structural intervention, rendering it
more difficult to speak of CE of different interventions.
Although efforts are underway [15], more explicit defini-
tions of what specific services come under each heading
are needed to improve CE comparability across countries
and programs.
High-income countries were excluded because of several
reasons: the bulk of the new infections come from low-
and middle-income economies, and thus it is in those
countries where the largest impact in terms of HIV infec-
tions averted can be made; more developed countries
have more resources to spend on health and with rela-
tively less scarcity comes less competition for life-saving
interventions; the differences in transmission types and
the socio-cultural context warrant a separate analysis by
income level [1,16,17].
To summarize the information obtained from the individ-
ual studies, we created graphs depicting the HIV-preven-
tion interventions in terms of their cost per DALY [18],
both in absolute terms and as percentage of the country-
specific per-capita gross domestic product (GDP) [19].
Results
Table 2 presents a summary of the studies addressing CE
of the HIV-prevention interventions, by type of interven-
tion. From the 21 distinct CE studies identified, five
addressed behavior change interventions; seventeen dealt
with biomedical interventions; and three analyzed struc-
tural/environmental interventions (the total number of
interventions studied adds to 25 because one study dealt
with several interventions at once).
In terms of the regional and epidemic type (defined in
Additional File 1), we found sixteen studies from sub-
Saharan Africa (low- and high-level generalized epidem-
Table 2: HIV Prevention Cost-effectiveness studies, 2005 - 2008
INTERVENTION # of studies REFERENCES
Behavior Change
• Voluntary counseling and testing 3 Hausler, Sinanovic et al 2006; Hogan, Baltussen et al. 2005; John et al 2008 [20-22].
• Treatment for addictions 1 Vickerman, Kumaranayake et al. 2006 [23].
• School-based interventions 1 Hogan, Baltussen et al. 2005 [21].
Biomedical Interventions
• Antiretroviral therapy 1 Over, Marseille et al. 2006 [24].
• Prevention of Mother-to-Child Transmission 5 Hogan, Baltussen et al. 2005; Reynolds, Janowitz et al. 2006; Soorapanth, Sansom et 
al. 2006; Maclean and Stringer 2005; Teerawattananon, Vos et al. 2005; [21,25-28].
• Treating STIs 5 Hogan, Baltussen et al. 2005; Vickerman, P., F. Terris-Prestholt, et al. 2006; Price, 
Stewart et al. 2006; Oster 2005; White, Orroth et al. 2008 [21,29-32]
• Male Circumcision 5 Kahn, Marseille and Auvert 2006; Gray, Li et al 2007; Martin, Bollinger et al. 2007a; 
Martin, Bollinger et al. 2007b; White et al 2008 [33-37].
• Female Condom 1 Dowdy, Sweat et al. 2006 [38,39].
Structural/Environmental Interventions
• 100% Condom 1 Sweat, Kerrigan et al. 2006 [38,39].
• Women empowerment/Social/Peer-based 
programs/mass media
2 Hogan, Baltussen et al. 2005; Fung, Guinness et al. 2007 [21,40].BMC Public Health 2009, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2458/9/S1/S5
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ics), four from Asia (low-level generalized and concen-
trated epidemics), two from Latin America (concentrated
epidemics) and only one from Eastern Europe (concen-
trated epidemic). The total is 23 because two studies dealt
with two regions. See Additional File 1.
In the remainder of this section, we summarize the find-
ings by type of intervention.
Behavior change interventions
The aim of behavior change interventions is to reduce the
risk of HIV infection through modification of sexual and
addiction-related behaviors [14]. Studies were found in
this category for voluntary counseling and testing (VCT),
treatment for addictions (alcohol and drugs), and school-
based programs.
Voluntary counseling and testing
A study in Cape Town, South Africa [20], measured the
costs and CE of the ProTEST, a package aiming to decrease
HIV transmission through voluntary counseling and test-
ing (VCT). The authors collected annual cost data retro-
spectively using ingredient-based costing in three primary
care facilities, and estimated the cost per HIV infection
averted (HIA) and the cost per TB case prevented. The esti-
mated cost per HIA by VCT in ProTEST was US$ 67 in the
STI clinics and US$ 112 in the community clinics [20].
Although they found only moderate adherence, the link
between prevention and care interventions for tuberculo-
sis (TB) and HIV resulted in the estimated costs of pre-
venting TB being less than previous estimates. VCT was
found to be less expensive than previously reported else-
where in Africa, primarily because the cost per client for
post-test counseling was lower in STI clinics than in the
other facilities because of the high number of people
being tested and the use of lay counselors.
A generalized CE estimate for VCT in sub-Saharan Africa
reported US$ 1,315 per HIV infection averted and US$ 82
per DALY [21]. Generalized CE refers to studies where the
reference case is the null set, or no intervention; contrast-
ing with intervention-mix constrained (IMC) CE, where
the reference case is the current program or the status quo
[41]. Some of the CE estimates have been estimated for
regions as a whole, even though the effectiveness of the
basic programs has not been conclusively demonstrated.
The VCT intervention evaluated in the study was assumed
to be performed in a primary care setting for any client
who requested services. The costs included health-worker
training, and rapid tests. The VCT impact was based on the
number of individuals expected to complete the testing
and the regional risk group-specific HIV prevalence.
A study from Kenya [22] found that infant HIV infections
can be averted for less than US$ 483 per HIA using either
of the two options explored: individual or couple coun-
seling. The study reported that voluntary VCT for couples,
although more expensive, averted more infant infections.
The cost per DALY for couple VCT was similar to that of
individual VCT. The sensitivity analyses found that couple
VCT became more cost-effective as HIV prevalence and/or
uptake of couple counseling increased.
Treatment for addictions
Vickerman and colleagues [23] explored the CE of a harm-
reduction intervention among injecting drug users (IDUs)
in Odessa, Ukraine, including the implications of success-
fully scaling up the intervention to reach 60% coverage as
per WHO/UNAIDS guidelines. They used a dynamic
mathematical model to fit the epidemiologic data and
project the intervention's impact. Using the 1999-2000
coverage of 20-38% and an HIV prevalence among IDUs
of 54%, 792 HIV infections could be theoretically averted,
a 22% decrease in IDU HIV incidence. The cost per HIV
infection averted would be US$ 97. Scaling up the inter-
vention to reach 60% coverage would remain cost-effec-
tive and it would reduce HIV prevalence by 4% over a 5-
year horizon [23].
School-based interventions
A generalized CE study determined the CE of school-
based education (against the counterfactual of no inter-
vention) as follows: US$ 6704-9448 per HIA (or 376-530
per DALY) in Africa; and 7288-13,326 per HIA (or 432-
790 per DALY) in South East Asia [21]. The target popula-
tion was school-age youth (10-18 years old); sessions
were provided during regular lessons to all students with
the aim of promoting prevention of HIV and other STIs;
teacher-training costs were included. The variation in
incremental cost-effectiveness ratios (ICERs) resulted
from using different assumptions about coverage rates.
Biomedical interventions
Biomedical interventions harness technology to prevent
HIV/AIDS. These comprise chemical and physical strate-
gies targeting biological and physiological processes that
are responsible for HIV acquisition and transmission [13].
These include interventions already in widespread use as
well as ones recently introduced and under development
(e.g., male and female condoms, blood screening, treat-
ment of STIs, pre- or post-exposure ART, PMTCT, male cir-
cumcision, microbicides, vaccines, and vaccination
against viral infections, such as the human papillomavi-
rus, herpes and hepatitis A and B).
Antiretroviral treatment and prevention of mother-to-child 
transmission
A generalized CE study reported the CE of prevention of
mother-to-child transmission (PMTCT) to be US$ 34 per
DALY averted in Africa and US$ 310 per DALY averted inBMC Public Health 2009, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2458/9/S1/S5
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Asia [21]. Another study analyzing antiretroviral therapy
(ART) and prevention in India reported a CE range of
US$145-280 per DALY averted with ART if enhanced with
any of three prevention strategies considered: improved
adherence to therapy; treatment for PMTCT+ (the + indi-
cates that treatment would be available also for eligible
husbands); and subsidies for ART for people living below
the poverty line [24]. If antiretroviral treatment could be
delivered in a way that also scaled up prevention efforts
(mainly through increased condom use), the costs per life
saved dropped to about US$ 10-30.
Because of practical and/or ethical concerns, actual inter-
ventions cannot always be implemented with all the ideal
features for an evaluation. Modeling, then, becomes a use-
ful alternative. One such case is a study that modeled pre-
vention options in a hypothetical generalized high-level
epidemic in sub-Saharan Africa, and estimated a cost of
US$ 857 per HIV-positive birth averted with a single-dose
nevirapine regime [25]. Interestingly, the study showed
that prevention of unintended pregnancies would cost
US$ 663 per HIV-positive birth averted; thus, family plan-
ning was a more cost effective way of preventing mother
to child transmission than nevirapine-based HIV preven-
tion.
A decision analysis model [26] carried out from the per-
spective of the health-care system in a generalized, high-
level epidemic (such as South Africa and other resource-
limited settings) assessed the CE of HIV rescreening dur-
ing late pregnancy, using prevention of perinatal HIV
transmission as the main outcome. HIV rescreening in the
third trimester of pregnancy was found to be cost saving
when ART was available for HIV-infected newborns.
Providing ART to mothers who are breastfeeding has also
been analyzed from a CE perspective in the context of a
hypothetical cohort of 40,000 pregnant women in sub-
Saharan Africa. Providing daily infant NVP and breast-
feeding for 6 months was the economically preferred strat-
egy with an ICER of US$ 79 per QALY gained [27].
A study from Thailand [28] modeled a hypothetical
cohort of 100,000 pregnancies and used a decision tree
with various program options. The cost and outcome data
were based on Thai settings. The combination of one and
two VCT sessions, and four antiretroviral therapy regi-
mens led to eight case options. One VCT session with
AZT+NVP would avert 337 cases of infection at US$ 556
per case averted; thus, the program combining AZT and
NVP had the lower cost per pediatric HIV infection
averted.
Treatment of sexually transmitted infections
Controlling STIs has continued to be a policy option for
HIV prevention around the world and a number of new
studies have emerged. A study assessing an STI program
for female sex workers (FSWs) in hotels in Johannesburg,
South Africa, found the intervention effective in averting
HIV infections [29]. The full intervention included con-
dom distribution, treatment of symptomatic STIs and
periodic presumptive treatment (PPT). A mathematical
model fitted to the epidemiological data estimated that
the cost per HIA was US$ 2,093 (range, US$ 1,384-3,635),
or US$ 78 per DALY averted (with a range of $53-121).
A modeling study in Malawi involving a semi-urban pop-
ulation of men treated for Trichomonas vaginalis, where
HIV prevalence was 44%, showed that treating all men
would result in a decrease of 4.5% in the number of new
HIV infections; trichomoniasis was responsible for 27.2
new cases of HIV in this sub-group population [30]. The
costs of screening for trichomoniasis ranged between US$
2 and US$ 62 per infection averted. The CE results showed
that with 100% coverage the ICER over the status quo was
$15.42 per HIA.
More generally, a modeling exercise for the African conti-
nent as a whole [31] reported that an intervention affect-
ing HIV transmission rates through improved STI
treatment could save 291 million life years with 13 mil-
lion infections averted. That could be achieved at a cost of
around US $78 per infection.
An epidemiological model simulating four HIV epidemics
in West and East Africa [32] estimated the population-
attributable fractions of incident HIV attributable to STIs.
The cost per HIA range was US$ 321-1,665. The authors
concluded that curable STI interventions remained cost-
saving when compared to lifetime HIV treatment costs (of
$3,500) in generalized HIV epidemics, in populations
with high-risk behaviors or with low male-circumcision
rates.
Male circumcision
Unlike other HIV prevention strategies, male circumcision
(MC) is a one-time procedure with lifelong protective
benefits and thus potentially highly cost-effective. The
first CE study of MC used a mathematical model to simu-
late population-level MC in Gauteng, South Africa where
one of the initial randomized, controlled trials (RCTs)
was conducted [33]. Using a hypothetical group of 1,000
men 18 years and older, the study estimated the CE of pro-
viding MC services per HIV infection averted to be
US$181. The cost of performing one MC (including med-
ical costs of the procedure, community publicity as well as
cost of treating adverse events) was estimated to be US$
55. With a population prevalence of 25%, over a 20-yearBMC Public Health 2009, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2458/9/S1/S5
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period, the 1,000 MCs would avert 308 adult HIV infec-
tions resulting in US$2.4 million in net savings due to the
HIV medical costs averted over a lifetime. According to the
study, the higher the MC coverage, the more cost-effective
the intervention would be.
Another study conducted for a cohort in Rakai, Uganda
used a stochastic model to simulate the impact of MC on
HIV incidence, infections averted and cost [34]. The
researchers developed different estimates for various lev-
els of efficacy (40-60%) and circumcision coverage (25-
100%). With the cost per HIA ranging between US$ 1,269
and US$ 3,911 at 75% coverage, the study found MC to
be cost-effective even at a higher cost of US$69 per cir-
cumcision.
Studies by Martin, Bollinger and colleagues in Lesotho
and Swaziland [35,37] provide MC cost and CE estima-
tions. Both country-case studies used the same cost-esti-
mation methodology modeled on an all-ingredients
analysis of providing MC to 15-49 year old men at a cov-
erage rate of 52.5% (Lesotho) and 57.5% (Swaziland)
during the next twelve years (2008-2020). CE was
assessed using cost per HIA and number of HIA per cir-
cumcision. The CE was found to be US$ 292 in Lesotho
and US$ 176 in Swaziland. One HIV infection would be
averted for every 6.1 and 4.1 circumcisions, respectively,
in Lesotho and Swaziland. It is notable that the CE analy-
sis was dependent on when in the roll-out the estimation
was made, as well as the pace of implementation. The
results showed that MC would be a highly cost-effective
intervention.
An individual-based model fitted to the characteristics of
an illustrative high-HIV-prevalence population in sub-
Saharan Africa [36] found the costs (in 2007US$) per HIA
in adults, by the intervention targeted at 15-49 year old
men, over 2, 20 and 50 years to be US$ 1,806 (1327-
3554), 195 (143-356) and 89 (71-150), respectively. Over
the first 10 years of the intervention, the CE estimate was
highest if the targeting was directed at 25-34 year-old
men. Moreover, targeting any adult-age group was esti-
mated to be a cost-saving strategy when compared to HIV
lifetime treatment costs. In the short-run, however, target-
ing newborns or young males before their sexual debut
was not cost-saving because circumcision occurred many
years before men experience their highest HIV infection
risk. Nevertheless, the intervention directed at neonates
became as cost-effective as targeting adults after 20 years.
Female condom
Dowdy and colleagues [38], in a study of the CE of the sec-
ond-generation female condom (nitrile female condom
or FC2), showed the usefulness of analyzing the synergies
between current unit costs and current CE vs. volume dis-
counts or global purchasing arrangements and future CE.
The results showed that in Brazil an HIV infected could be
averted for US$ 20,683. In South Africa the ICER was US$
985 per HIV infection averted.
Structural interventions
Structural interventions attempt to change the underlying
determinants of risk, vulnerability or disease. These pro-
grams may be called social, environmental, ecological, or
upstream interventions. They are varied in nature and
include changes in laws, prices and/or taxes, subsidies,
vouchers, housing, income-generating activities, women
empowerment, etc. [12].
100% condom
Sweat and colleagues [39] analyzed how laws with strong
consequences, and with positive rewards, can be instru-
mental in achieving better HIV prevention results in the
female sex industry in the Dominican Republic. They
found that the cost per HIA was US$ 10,856; or US$ 457
per DALY in Puerto Plata (structural approach with legal
changes); versus US$ 28,208 per HIA and US$ 1,186 per
DALY saved in Santo Domingo (traditional information,
education, and communication, IEC) [39].
Empowerment/social/peer-based programs/mass media
Work by Fung and colleagues [40] reports on a prevention
intervention for commercial sex workers (CSW) compar-
ing changes in sexual behavior and condom use in
Ahmedabad City (the seventh largest city in India) in
which rates of HIV prevalence are particularly high among
CSW. The CE study included four strategies with peer edu-
cators: increasing knowledge of HIV/AIDS and STIs,
improving STI treatment of CSW and their clients, increas-
ing safer practices, and environment improvement. All
strategies were compared with no intervention. The costs
per infection averted ranged from US$ 33.7 to $133.4
when peer educators where valued as financial costs, and
from $55.6 to $128.5 when considered as economic costs.
Similarly, the cost per DALY averted was: US$ 3.1 (1.9-
7.5) to 5.5 (3.1-12.3) for the two scenarios.
A generalized CEA [21] of a mass-media campaign esti-
mated the cost per HIA at US$ 58 per HIV infection or US$
3 per DALY (ICER compared to no intervention). The
campaign analyzed included television and radio epi-
sodes and inserts in the most influential newspapers,
repeated every two years; development and administra-
tion costs were included; the effectiveness was scaled by
proportion of population reporting weekly exposure to
radio, television, or newspapers.
Summarizing the HIV prevention cost-effectiveness results
Figure 1 shows a summary of the CE studies of HIV-pre-
vention interventions in Africa, classified by type of inter-BMC Public Health 2009, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2458/9/S1/S5
Page 7 of 14
(page number not for citation purposes)
vention (behavioral, biomedical or structural). On the
horizontal axis we have cost per DALY as the percentage of
the country-specific per-capita gross domestic product
(GDP) at current US dollars (of the year of the costing, as
specified in each study) [19]. On the vertical axis we have
the cost per DALY (log transformed). The figure shows
that most of the studies of HIV prevention CE for Africa
are of biomedical interventions. Some variability is
observed, but generally the interventions are highly cost
effective: most fall below a threshold of US$100/DALY.
Similarly, the great majority of interventions cost less than
30% of one per-capita GDP and only one costs more than
60% of one per-capita GDP. Health interventions are
deemed highly cost effective if they are below a threshold
of one (or 100% of) per-capita GDP [42].
Moreover, Figure 1 shows a clustering of biomedical inter-
ventions for the African region. The clustering mostly rep-
resents a number of recent PMTCT and MC studies, which
are clearly some of the most cost effective options among
the different HIV-prevention interventions.
Similarly, Figure 2 shows a summary of the HIV-preven-
tion interventions in regions other than Africa (i.e., Latin
America, Asia and Central Europe), classified by type of
intervention (behavioral, biomedical or structural). The
axes are the same as in Figure 1. Most of the studies of HIV
prevention CE for other regions are also for biomedical
interventions. Some variability is observed, but generally
the interventions are cost effective: a few interventions
cost about $1,000/DALY but most fall well below that
threshold; and in relative terms, most cost less than 50%
of one per-capita GDP, and only one intervention was
about 60% of GDP per capita. Note that some of the inter-
ventions in other regions (in contrast to Africa) cost rela-
tively more, when compared to their own GDP per capita;
this is related to higher expenditures in health and the
lower HIV prevalence rates. Nevertheless, the general dis-
tribution of the CE results is strikingly similar between
Africa and other regions.
Discussion
A prior HIV review presented in the book on Disease Con-
trol Priorities in Developing Countries [3] found no CE stud-
ies in the areas of: surveillance, IEC, MTCT feeding
substitution, IDU drug substitution, universal precau-
tions, vaccines and behavior change for HIV positive peo-
ple. In this review, we have found newer CE studies which
cover some of the previously unexplored areas: IEC [39],
behavior change among people initiating ART [24], male
circumcision [33-37] and harm reduction for IDUs [23].
However, there are still multiple interventions whose CE
has not been assessed and several more for which the evi-
dence is very limited. There continues to be a lack of any
CE work on prevention for or with positives, which has
become more important as HIV treatment expands
throughout the world. Most of the studies reviewed
focused on sub-Saharan Africa; only a handful were based
in Asia and Latin America. As there are fewer studies for
concentrated epidemic settings, it is not surprising that we
found no CE studies for the most vulnerable groups in
concentrated epidemics. For example, there is still no CE
HIV Prevention Cost per DALY vs. percent GDP per capita (Africa) Figure 1
HIV Prevention Cost per DALY vs. percent GDP per capita (Africa). Notes/Sources: The graph plots the studies 
reviewed in terms of US$ cost per DALY and the same US$/DALY as percent of country-specific per-capita gross domestic 
product (GDP) taken from the International Monetary Fund, World Economic Outlook Database [19]. US$/DALY is the cost 
per disability-adjusted life year, DALY (US dollars, year of costing as reported in each study, log transformed). When cost/
DALY was not available in the studies, we assumed it was equal to the cost per infection averted/20 for adults, 25 for children 
[3,18]; one study used cost per QALY [25]. For details of each study, see Additional File 1.BMC Public Health 2009, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2458/9/S1/S5
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evidence regarding men who have sex with men (MSM) or
male sex workers (MSW) in Latin America, or any studies
about inmates or other captive populations.
An examination of the summary graphs (Figures 1 and 2)
reveals several important points. First, all HIV-prevention
interventions reviewed here are highly cost effective; that
is, the cost per DALY is far less than one GDP per capita;
and most interventions in Africa cost less than 30% of one
GDP per capita and 40% in other regions. Second, all
HIV-prevention interventions reviewed are cost effective
when compared to other life saving interventions includ-
ing HIV treatment, which is consistent with other recent
comparative results [43-45]. Third, a "handle with care"
caveat is absolutely essential. Based on the literature
results, as they are published, we cannot differentiate with
certainty which intervention types of the three (behavio-
ral, biomedical and structural) seem to be more CE than
others, all the more so because the studies reviewed did
not consider interactions between different types of inter-
ventions. Likewise, inter-country or inter-study compari-
sons are problematic in the literature because the base-
case scenarios are different, and there are many uncertain-
ties and unknowns when deciding how to model the CE
of HIV prevention. Most importantly, the question of the
actual effectiveness of many of the modeling exercises
may be misleading for policymakers. In the remainder of
this section, we point out some of the specific limitations,
first by type of intervention, and then by specific issue.
Behavior change interventions
Because only modest evidence of effectiveness exists for
school-based interventions in terms of HIV prevention
[46-48], as well as limited costing data [48], it is not sur-
prising that we found only one generalized CE study
focusing n school interventions [21]. International experi-
ence with HIV prevention programs at the school level is
ample, but it is a controversial subject. Comprehensive lit-
erature reviews for developing countries [46,47,49,50]
suggest that programs at the school level can have a posi-
tive impact on attitudes and knowledge of HIV/AIDS and
other STIs. The results indicate that many of the interven-
tions have not been fully successful in obtaining the stated
goals of modifying the risk behaviors and postponing ini-
tiation of sexual activity, reducing the number of sexual
partners, and reducing the number of unplanned adoles-
cent pregnancies. In addition, many programs have not
strongly demonstrated an effect on consistent condom
use or sexual abstinence. Hence, with such limited effec-
tiveness information, it is difficult to show realistic CE
results.
The evidence for the effectiveness of voluntary counseling
and testing on HIV incidence is also ambivalent. Although
some experimental evidence has shown that VCT can pro-
mote preventive behaviors [51], a recent meta-analysis of
VCT in developing countries concludes that there is only
a moderate effect of VCT in reducing unprotected sex and
inconclusive evidence for the effect of VCT on the number
of sexual partners [52]. Prior systematic reviews and meta-
analyses showed similar mixed results [53]. A cluster-ran-
HIV Prevention Cost per DALY vs. percent GDP per capita (other regions*) Figure 2
HIV Prevention Cost per DALY vs. percent GDP per capita (other regions*). Notes/Sources: *Other regions are 
Latin America, Asia and Central Europe (Ukraine). The graph plots the studies reviewed in terms of US$ cost per DALY and 
the same US$/DALY as percent of country-specific per-capita gross domestic product (GDP) taken from the International 
Monetary Fund, World Economic Outlook Database [19]. US$/DALY is the cost per disability-adjusted life year, DALY (US 
dollars, year of costing as reported in each study, log transformed). When cost/DALY was not available in the studies, we 
assumed it equals cost per infection averted/20 for adults, 25 for children [3,18]; one study used cost per life year [24]. For 
details of each study see Additional File 1.BMC Public Health 2009, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2458/9/S1/S5
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domized trial in Zimbabwe showed that uptake of VCT
services continues to be low, prompting consideration of
new strategies to improve uptake, such as workplace-
based alternatives [54]. Nevertheless, we found a study in
Colombia [55] that presents a decision tree to compare CE
of three strategies for HIV screening of pregnant women:
voluntary, universal and optional. The study includes all
women with unknown HIV status admitted for child birth
in the country. For every HIV-positive newborn case
detected, the universal screening strategy is less costly
(US$ 17) than the optional (US$ 24) and the voluntary
(US$ 38) strategies. However, as this study does not
present costs per HIA it was not presented in the results
section.
Biomedical interventions
It is not unexpected that no studies of CE on microbicides
have been published in the last four years, given the
mostly disappointing news from the clinical trials [56-
58]. Similarly, progress on a vaccine for HIV has been slow
[59]. An international vaccine trial was discontinued in its
second phase after interim analysis showed that the vac-
cine efficacy could not be obtained [60,61] and that it
may actually make the subjects more susceptible to HIV
[62,63]. So far, the only vaccine candidate to complete a
phase III efficacy trial had no protective effect [64]. Fur-
thermore, experimental and policy challenges to the
development of a vaccine [65] make the hope more uncer-
tain [63]. Nevertheless, vaccine research has seen massive
investment estimated at about US$ 800 million a year
[66], as well as increased coordination efforts [67]. Mode-
ling estimates suggest that even a modestly efficacious vac-
cine could have a substantial impact on controlling the
epidemic and substantial financial savings; thus, the rea-
son to continue investing resources on developing an
effective vaccine [68].
Furthermore, other analysis on vaccines by Berndt and
colleagues [69] highlight the key role played by product
pricing, uptake rates, and efficacy in the CE analysis proc-
ess. In particular, they emphasize that CE estimates are
sensitive to market prices; but, in turn, market prices are
sensitive to volume discounts which can be achieved with
more cost effective interventions. The authors also find
that duration of protection would have a strong effect on
the CE of a vaccine.
Only one study [24] explicitly modeled the interaction
between ART and prevention, although some effective-
ness evidence does exist [70-73]. ART reduces viral load,
but it also increases physical wellbeing, and patients' abil-
ity to engage in sexual activity. Hence, the interactions
between providing ART and continuing prevention efforts
should be further explored in terms of CE.
STIs such as herpes simplex virus type 2 (HSV-2) may
increase HIV transmission [74]. The earliest study con-
ducted in Mwanza, Tanzania suggested that when STIs are
treated, HIV infection declined by almost 40% over a two
year period [75]. Following this result, STI treatment was
included in the catalogue of HIV prevention measures
endorsed by the WHO and UNAIDS [76]. However,
another RCT in Rakai Uganda showed contradictory
results [77] and other studies have not replicated the
Mwanza level of efficacy [78-81]. Prevention of STIs fol-
lows in general the same recommendations as HIV pre-
vention: reduction of number of sexual partners, condom
use, etc.; thus, prevention of STIs could in principle also
help to prevent HIV infection [82].
While some of the studies reviewed here suggest that treat-
ing STIs can be cost-effective, the epidemiological debate
continues about the effectiveness of treating STIs as a way
to prevent incident cases of HIV. The controversy, over
whether treating STIs has any impact on HIV, casts doubt
on the CE results reviewed here, or at least provides fur-
ther sources of uncertainty around them. Until the issue is
settled, one alternative for researchers may be simply to
limit the analysis to costs per STI treated. STI prevention
and treatment interventions can be beneficial and cost
effective in their own right. For example, an intervention
in Managua, Nicaragua [83] provided vouchers to sex
workers, their regular clients and/or partners, transves-
tites, and male glue-sniffers. It increased the treatment rate
of STIs (gonorrhea, Chlamydia, syphilis, and trichomo-
niasis) from 15% to 92% by making the services more
affordable and of higher quality. Moreover, the study
showed that the ICER was US$ 103 per STI cured. If per-
sonnel costs were reduced by 50%, the incremental CE
ratio would fall to US$ 83 per STI cured [83]. This study
was not analyzed in the results section as it did not pro-
vide costs per HIA or costs per DALY averted.
Among the biomedical interventions, male circumcision
stands out as highly cost-effective for the level of efficacy
demonstrated in the three RCTs. The five CE studies [33-
37] conducted in high-level generalized epidemics show
that investment in this intervention can result in averting
significantly large numbers of new HIV infections. How-
ever, for concentrated epidemics, studies are needed on
the effectiveness of MC among men who have sex with
men and on the CE among infants and among heterosex-
ual adults.
Structural interventions
Structural interventions include policy tools such as
changing the tax structure, sex industry regulation, prop-
erty rights and access to credit for women. Many of these
programs have been evaluated recently, but they have not
directly addressed HIV prevention, even though they mayBMC Public Health 2009, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2458/9/S1/S5
Page 10 of 14
(page number not for citation purposes)
have had the potential to do so. For example, Cohen and
Dupas [84] present results from Kenya where in-kind
incentives and price subsidies were used for malaria pre-
vention. Women were randomized to free or three (inter-
vention) price-levels of insecticide-treated bed nets if they
attended a health post where general health and HIV pre-
vention information was provided. They showed that
higher incentives (lower prices) directly increased the
uptake of bed nets. However, they did not directly link
attendance to treatment and PMTCT in the form of nevi-
rapine for HIV-positive mothers.
Similarly, experimental research in Malawi by Thornton
[85] suggests that even a small economic incentive (as lit-
tle as one tenth of daily wage) can increase the percentage
of people returning for their HIV test results to about 80%
(compared to the 39% of participants who return for HIV
test results without an incentive). Furthermore, HIV-posi-
tive individuals who learn their infection status are three
times more likely to purchase condoms. However, the
number of condoms purchased was small, only two on
average. Testing alone does not seem to be as cost effective
as other interventions [85].
Although few structural interventions measure HIV infec-
tions averted (HIA), the main outcome of interest, struc-
tural interventions in general and conditional cash
transfers [86] in particular could have a great potential to
alter behaviors and prevent HIV. Randomized controlled
trials are needed to test various hypotheses regarding the
optimal level of incentives, the best implementation strat-
egies, and the best conditions for testing and treatment
services. Structural and environmental interventions seem
to have the potential to improve the effectiveness and CE
of currently proven and new interventions. More experi-
mental and modeling evidence is needed to further
explore the effects of changes in laws, taxes, and economic
incentives on HIV prevention. A promising avenue may
be to add HIV and/or STI components to conditional cash
transfer interventions that have already proved to be effec-
tive in changing health behaviors in low- and middle-
income countries. Prospective trials need to be designed
carefully, measuring potential benefits as well as the pos-
sibility of unintended harm, e.g. spending the extra cash
to buy drugs or alcohol. Also, a great challenge in condi-
tional cash transfer (CCT) programs is the supply side
(quality of services); this is particularly important for pop-
ulations such as MSM who often do not use public serv-
ices because of the discrimination they encounter.
Intervention bundles and synergies
Interventions in the context of programs are usually bun-
dled; for example VCT and condom promotion may be
provided at the same time. This not only makes it more
difficult to evaluate the impact of a single intervention, it
suggests that effectiveness is dependent not only on how
an intervention is implemented, but also on what other
interventions are bundled with it [3,87]. Better evaluation
designs (including multiple-arm controlled trials) may be
required so that each component, their synergies, as well
as total effects, can be estimated. Only when information
is available about the likely synergies between different
prevention interventions will CEA realize its potential in
helping to identify the optimal package or the "right mix"
for a given country or situation.
The synergies between prevention and treatment can also
be analyzed using a CE approach. At a basic level, it is clear
that if prevention is enhanced, there will be less treatment
needed in the future. As treatment efforts become more
widespread, prevention among HIV positive individuals is
essential to reduce HIV transmission. As noted already, we
did not find any CE studies on prevention for or with pos-
itives. The typology needs to be updated also: can preven-
tion for people with HIV be similar, or are there
prevention interventions that are specific and different for
the positive population? In general, we have little empiri-
cal information about the interactions between different
prevention and treatment strategies [88]. More research is
needed in the area of prevention for positives.
Scale, cost functions and nonlinearities
Many unknowns remain in the relationship between scale
and costs [89]. Particularly, in high-level generalized epi-
demic settings, there is still no clear CE evidence on how
to achieve a scale sufficiently large to have a major impact
on HIV incidence. For example, male condoms continue
to be one of the most widely used interventions, yet there
is no recent CE evidence on how to achieve higher rates of
condom utilization.
Unit costs can decrease considerably with scale across
many programs in different settings, but there can be
important differences within the same country [90]. Also,
non-linear relationships between unit costs and scale can
occur [91]. The shape of the cost function [92] can reveal
very different unit costs, and thus very different CE, at dif-
ferent scales of implementation. These effects are almost
universally ignored in the studies reviewed here and for
the DCPP [3,89]. Non-linear effectiveness with scale is
also an under-explored area, touched upon just by some
of the MC studies reviewed here. Modeling work by Mar-
tina Morris and others [93] suggests that the relationship
between behavior change and epidemic behavior can be
far less linear than typically assumed in most CE models.
For some basic interventions (such as male condoms),
there are estimates of the threshold at which the reproduc-
tive rate (R0) for the epidemic (i.e., the number of second-
ary cases caused by a primary case over the lifetime of thatBMC Public Health 2009, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2458/9/S1/S5
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infected person) goes below unity [94]. R0 may be useful
as a theoretical outcome measure [95]. However, a
number of model assumptions are needed to estimate at
which point an intervention reaches R0 < 1. To estimate it
empirically would require precise knowledge of how HIV
is transmitted in each setting, and detailed information on
sexual behaviors and networks. Moreover, the relevant
question is whether a specific package of prevention inter-
ventions can achieve an R0 < 1; it is a less useful concept
for one intervention considered in isolation.
The specific effects of condom use on the dynamics of the
epidemic are likely to be nonlinear. Similarly, the effects
of ART on HIV transmission, due to its impact on longev-
ity and sexual activity, are another example of nonlinear
impacts which have been overlooked.
Lack of standard, transparent methods
The literature continues to have only a few studies per type
of intervention, not always with standardized and trans-
parent methods, which does not facilitate comparison of
results. Thus, the limited CE evidence is difficult to use in
policy planning. Few studies report how their results have
been used in weighing policy alternatives. Moreover, the
studies do not generally discuss how to interpret results in
terms of thresholds, nor do they explore budgetary con-
straints and acceptability curves that would provide useful
information to policymakers.
Modeling techniques to assess the CE of one or more
interventions continue to be widely used. Models are a
useful resource to estimate final outcomes when data are
not available. However, modeling on untested assump-
tions can be a disservice for policy because it may raise
false expectations of programs, as there are still many
empty cells in the effectiveness matrices [96]; thus, many
CEA studies can be highly speculative. More efforts should
be made to compare models and develop international
guidelines to provide readers with tools to evaluate the
results and assumptions of a model. The WHO-CHOICE
project [42] has provided some guidelines. Additional
challenges are to have the guidelines followed, and find-
ing the right tools to translate results from complex mod-
els to decision-makers.
Publication bias
Effectiveness studies that fail to show effectiveness would
have no reason to include a CE component because an
intervention without demonstrable effectiveness would
have an infinite cost per unit of benefit. Thus, some of the
peer-based programs, school education studies, STI treat-
ment or the comprehensive community-prevention trials
that have failed to show benefit should be assigned an
infinity cost per DALY estimate [3]. Nevertheless, some
CEA studies continue to include an implicit cost per unit
of benefit based on selective assumptions.
Conclusion
A number of CE studies of HIV-prevention interventions
have become available in the past four years. As a body of
work, they provide important information by analyzing
CE ratios which depend upon a variety of factors includ-
ing epidemiological characteristics, population targeted,
coverage, unit prices and the technical efficiency for
implementation. Focusing on the interventions that are
most likely to be cost effective could help countries move
from small, isolated programs to large-scale, comprehen-
sive prevention efforts. Given the limited resources, as
new and potential interventions are shown to be effective,
they need to be fully analyzed in terms of their CE. This
review shows that many HIV-prevention interventions are
cost effective in absolute terms (using costs per DALY
averted), and also in country-specific relative terms (meas-
ured as percentage of GDP per capita).
Nevertheless, a number of observations can be made
about the state of the literature. First, we do not have CE
studies for each epidemic type, even for the most com-
monly recommended or implemented HIV-prevention
interventions. Second, scale-up scenarios often assume
that relationships are linear, when there may be nonline-
arities and economies and/or diseconomies of scale.
Third, substantial uncertainty of unit costs and effects
result in uncertain CE estimates, which makes difficult
comparisons among interventions (even with the aid of
league tables); we need to recognize that the degree of
error (both measurement and estimation) can be substan-
tial. Fourth, CEA in HIV prevention lacks consistency
among studies. The international efforts on CE have
developed useful guidelines, but few researchers use
them. Fifth, CEA is useful as it presents results in a way
that shows potential impact given a budget to spend on
mutually exclusive alternatives. The problem is that in the
real world the alternatives are seldom mutually exclusive
due to special interests, political and equity concerns.
Decision-making at the local level is never simply choos-
ing the most cost effective alternative.
More than 25 years into the AIDS epidemic and billions
of dollars of spending later, there is still much work to be
done both on costs and effectiveness to adequately inform
HIV prevention planning.
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